- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Authors
Latest:
That Was Then, This Is NowWhen Aligning Forces started, federal policy was a desert. Now it's a greenhouse.
Latest:
Treatment Patterns, Healthcare Utilization, and Costs of Chronic Opioid Treatment for Non-Cancer Pain in the United StatesHealthcare utilization and costs increased in the 6 months after patients started opioid therapy for chronic pain; they then decreased but never reverted to baseline levels.
Latest:
Validating the Adapted Diabetes Complications Severity Index in Claims DataThe aDCSI without the inclusion of laboratory data performs similarly to the DCSI with laboratory results, and is a good measure of diabetes severity.
Latest:
Physician Organizations’ Use of Behavioral Nudges to Influence Physician BehaviorPhysician organizations are applying behavioral nudges to influence physician behavior; however, their use is limited to a narrow range of clinical applications.
Latest:
Hepatitis B Virus Infection Testing and Prevalence Among Asian and Pacific IslandersWe examined the effect of country of origin on HBV testing and chronic HBV infection prevalence among APIs using data from Kaiser Permanente Hawaii.
Latest:
Insurers’ Perspectives on MA Value-Based Insurance Design ModelThis article describes perspectives of Medicare Advantage (MA) insurers about participating in the CMS value-based insurance design model test launched in 2017.
Latest:
Overcoming Barriers to a Research-Ready National Commercial Claims DatabaseLessons learned about data governance and distribution from a voluntary healthcare claims repository, the Health Care Cost Institute, a nonprofit research organization
Latest:
Putting the Pieces Together: EHR Communication and Diabetes Patient OutcomesMore frequent electronic health record (EHR) message forwarding in primary care teams is associated with worse outcomes and higher medical costs for patients with diabetes.
Latest:
Compliance, Persistence, and Switching Patterns for ACE Inhibitors and ARBsThis drug-utilization study in a prescription database of more than 50,000 patients analyzed compliance, persistence, and switching behavior for ACE inhibitors and ARBs.
Latest:
A Medicare Appeal for CGM Coverage: One Patient's Never-Ending StoryThe author, who has lived with type 1 diabetes for more than 50 years, shares his account of a successful appeal of Medicare's policy of refusing to pay for continuous glucose monitoring (CGM).
Latest:
Changing Electronic Formats Is Associated With Changes in Number of Laboratory Tests OrderedA slight decrease in the convenience of ordering a laboratory test led to a dramatic decrease in test utilization.
Latest:
Humanistic and Economic Burden of Hepatocellular Carcinoma: Systematic Literature ReviewWorldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the humanistic and economic burden of HCC.
Latest:
Improving Influenza Immunization in Pregnant Women and Healthcare WorkersInfluenza vaccination rates in pregnant women and healthcare workers were increased with standing orders, vaccine advocates, and educational activities on influenza immunization.
Latest:
Cost-Effectiveness of Pharmacist Postdischarge Follow-Up to Prevent Medication-Related AdmissionsA multivariable sensitivity analysis conducted on a pharmacy follow-up program of high-risk patients demonstrated cost savings to hospitals in 98.3% of head-to-head trials across 1000 hypothetical hospitals.
Latest:
Oral Anticoagulant Discontinuation in Patients With Nonvalvular Atrial FibrillationThe risk of discontinuation of oral anticoagulant therapy (both warfarin and direct oral anticoagulant therapies [DOACs]) among nonvalvular atrial fibrillation patients was high. Although the hazard ratio for discontinuation favors DOACs, it is unlikely that the small difference in discontinuation relative to warfarin is clinically meaningful.
